Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial

Diabetes Care. 2019 Apr;42(4):e53-e55. doi: 10.2337/dc18-1355. Epub 2019 Jan 31.

Authors

Silvio E Inzucchi¹, Christoph Wanner², Uwe Hehnke³, Isabella Zwiener³, Stefan Kaspers³, Douglas Clark³, Jyothis T George³, Bernard Zinman⁴

Affiliations

¹ Section of Endocrinology, Yale University School of Medicine, New Haven, CT silvio.inzucchi@yale.edu.
² Department of Medicine, Würzburg University Clinic, Würzburg, Germany.
³ Boehringer Ingelheim International GmbH, Ingelheim, Germany.
⁴ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada.

PMID: 30705060
DOI: 10.2337/dc18-1355

No abstract available

Publication types

Letter